Dr Li on the Investigation of BDC-1001 in HER2-expressing Solid Tumors
Oncology Live – June 13, 2023
C4C Taskforce Member Dr Bob T. Li discusses the results of a phase 1/2 study of the first-in-class immune-stimulating antibody conjugate BDC-1001 in patients with advanced HER2-expressing solid tumors.
